Navigation Links
MiMedx Group, Inc. to Present at the Noble Financial Capital Markets' Seventh Annual Equity Conference
Date:5/9/2011

MARIETTA, Ga., May 9, 2011 /PRNewswire/ -- MiMedx Group, Inc. (OTC BB: MDXG), an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it will present at the Noble Financial Capital Markets' Seventh Annual Equity Conference at the Hard Rock Hotel in Hollywood, Florida. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, Michael J. Senken, Chief Financial Officer and John Daniel, President of Surgical Biologics, a wholly-owned subsidiary of MiMedx, are scheduled to present on Tuesday, May 17th, at 1:00 p.m. Eastern Time. A webcast of this presentation will be available on the Company's website, www.mimedx.com.

About the Company

MiMedx is an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants manufactured from human amniotic membrane. The Company is successfully emerging from a development-focused start-up into a fully integrated operating company with an experienced team poised to capitalize on its science and technology to generate rapid sales growth and profitability. Our mantra is "Repair, don't replace" because our biochemists, engineers, designers and physicians believe it is better to augment repair when possible rather than replace traumatized, but otherwise healthy tissues and structures. Our platform technologies, HydroFix™ and CollaFix™, and our newest platform technology, Purion® developed by our wholly-owned subsidiary, Surgical Biologics, have a vast number of potential applications in treating traumatized tissue and structures and MiMedx is focused on commercializing multiple applications for the Company's three technology platforms. In parallel, we are seeking strategic relationships, in selective categories, to more rapidly commercialize our technologies.


'/>"/>
SOURCE MiMedx Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. MiMedx Group Announces First Quarter 2011 Results
2. MiMedx Group Announces 2010 Results
3. MiMedx Group, Inc. to Present at the 10th Annual Needham Healthcare Conference
4. MiMedx Announces Launch of AmnioFix™
5. MiMedx to Attend American Academy of Orthopedic Surgeons Annual Meeting
6. MiMedx Group, Inc. to Present at the 13th Annual Needham Growth Conference
7. MiMedx Group, Inc. Announces Release Date For Third Quarter Results
8. MiMedx Group, Inc. to Present at Noble Financial Sixth Annual Equity Conference
9. MiMedx Group Announces Temporary Trading Symbol Designation
10. Apexigen Announces the Filing by its Partner, Simcere Pharmaceutical Group, of First IND
11. Photonic Products Group, Inc. Announces New Sales and Marketing VP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Bellingham, Washington, USA, and Cardiff, UK (PRWEB) January 13, ... and photonics technology development leader with more than 20 ... international society for optics and photonics . Hainsey will ... “We are delighted to have Dr. Hainsey join SPIE ...
(Date:1/14/2014)... Rochester, NY (PRWEB) January 14, 2014 During ... is now known as “The Doctor’s Plague.” In this time ... their hands. This led, at times, to the death of ... staff today don’t know that they may be unwittingly transmitting ...
(Date:1/14/2014)... BioMedomics, Inc. , a Point of ... and novel disease specific POC tests, announced today that it ... total of $690,000. The investment is from private investors and ... group of private investors has significant successful experience in early ...
(Date:1/14/2014)... City, Panama (PRWEB) January 14, 2014 ... has received the county’s first clinical trial approval ... umbilical cord-derived mesenchymal stem cells (MSC) from the ... Review Board (IRB). , Rheumatoid Arthritis (RA) is ...
Breaking Biology Technology:Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 3
... Programs to Include Response Prediction to Ovarian Cancer ... Differentiation of Small Cell From Non-Small Cell Lung Cancer, In Addition, ... Cancer Patients, Which may Serve as the Basis for a Future ... Test ...
... Lead Discovery, COPENHAGEN, June 18 Nuevolution ... drug discovery collaboration with Merck & Co.,Inc., ... to identify novel small molecule leads against several ... uses innovative DNA,labeling to allow fragment-based drug screening ...
... HARTFORD, Conn., June 17 The Connecticut,Technology Council (CTC) ... in,partnership with accounting firm UHY LLP this November, to ... will be,recognized on the basis of revenue growth over ... and minimum revenues of $3 million in,the fourth year., ...
Cached Biology Technology:Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 2Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 3Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 4Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 5Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc. 2Connecticut Technology Council to Recognize Fast Growing Technology Companies 2
(Date:4/22/2014)... a five-year, $3 million study to determine whether an ... of dissolved organic matter (DOM) through the Connecticut River ... composition and water quality of the watershed and Long ... Foundation,s MacroSystems Biology program, researchers will collect data from ... Canada and runs through five U.S. states, before emptying ...
(Date:4/22/2014)... 2014) Biotechnology scientists must be aware of the ... licensing guidelines, according to a new paper from Rice ... the current issue of the journal Regenerative Medicine ... U.S. Supreme Court ruling in the case Association for ... genes are unpatentable. The court case and rulings garnered ...
(Date:4/22/2014)... Mass. Scientists at the University of Massachusetts Amherst ... Brazil, this week report that they have discovered a ... tributaries of the Negro River in the Amazonia State ... Amherst, with Adlia Nogueira and Jos Antnio Alves-Gomes of ... issue of the journal Proceedings of the Natural ...
Breaking Biology News(10 mins):Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3New electric fish genus and species discovered in Brazil's Rio Negro 2
... drug has lowered blood sugar levels and inflammation in mice ... be added to the arsenal of drugs used by millions ... The drug consists of a synthetic molecule that stops the ... or MIF. This protein is implicated in a number of ...
... the Australian National University, Research School of Chemistry, has ... Otting is on the editorial board of Springer,s ... Award is granted in recognition of a researcher,s entire ... had a significant impact on their own discipline. The ...
... and the University of Ottawa have identified a promising new ... the leading inherited cause of death in infants and toddlers. ... found that an enzyme called RhoA is overly active in ... can greatly increase survival. The study is published in ...
Cached Biology News:Study points to potential new drug for type 2 diabetes 2Study points to potential new drug for type 2 diabetes 3Study points to potential new drug for type 2 diabetes 4Study opens new avenue for developing treatments for genetic muscle-wasting disease 2
... developed specifically for the stabilization of ... plates/strips. Coating Stabilizer maintains the ... or protein antigen portion of the ... filtered at 0.2 microns., ,Contents: ...
... Novagen's HT96 Isothermal Block is an ... hold HT96 plates and to provide efficient ... plate. This new design of the HT96 ... offers an enhanced product design allowing for ...
Umbilical cord blood neutrophils, For immunohistochemistry (IHC)...
...
Biology Products: